Akero Therapeutics Inc Sustainability Reports
Akero Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing transformational treatments for serious metabolic diseases. Its lead product candidate is efruxifermin (EFX), which is evaluated for treating metabolic dysfunction-associated steatohepatitis (MASH).
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 549300SI3KG74LBE2955
FIGI: BBG00L9211Z7
4 reports from 2020 to 2024
